Literature DB >> 8478043

Implications of the systolic hypertension in the elderly program. The Systolic Hypertension in the Elderly Program Cooperative Research Group.

.   

Abstract

Several imperatives drive the need to establish the merit of treating isolated systolic hypertension in the elderly. These include its higher prevalence with age, the associated excess cardiovascular risks, and the rapid aging of the population. The Systolic Hypertension in the Elderly Program demonstrated a significant reduction in stroke incidence (fatal and nonfatal) (36%, equivalent to preventing 30 strokes per 1,000 participants per 5 years). A 27% reduction in coronary heart disease incidence and a 32% reduction in all major cardiovascular events were also achieved (equivalent to the prevention of 16 and 55 events per 1,000 participants per 5 years, respectively). These results were associated with a treatment regimen in which the primary agent was low-dose chlorthalidone. The benefits accrued to all subgroups identified based on baseline age, race and sex, blood pressure, serum cholesterol levels, and electrocardiographic abnormalities. The reduction in coronary disease is consistent with predictions based on prospective epidemiological studies and is concordant with other recent intervention trials. It is a reasonable inference from the Systolic Hypertension in the Elderly Program findings that middle-aged as well as older people with isolated systolic hypertension, and people with less severe degrees of this condition, particularly when other risk factors are present, would benefit from such therapy. Another reasonable implication of the trial relates to the matter of preferred drug treatment regimens for diastolic hypertension, in middle-aged as well as older people.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8478043

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  15 in total

Review 1.  Arterial aging: a review of the pathophysiology and potential for pharmacological intervention.

Authors:  Michael F O'Rourke; Audrey Adji; Mayooran Namasivayam; Jonathan Mok
Journal:  Drugs Aging       Date:  2011-10-01       Impact factor: 3.923

2.  Navigating the gray zones of stroke management for a graying population.

Authors:  Meng Lee; Bruce Ovbiagele
Journal:  Cerebrovasc Dis       Date:  2010-03-30       Impact factor: 2.762

Review 3.  Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus. Putting evidence into practice.

Authors:  S Vijan; D L Stevens; W H Herman; M M Funnell; C J Standiford
Journal:  J Gen Intern Med       Date:  1997-09       Impact factor: 5.128

4.  Clinical trials in isolated systolic hypertension.

Authors:  J Gasowski; J G Wang; J A Staessen
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

Review 5.  Management of isolated systolic hypertension.

Authors:  A Tonkin; L Wing
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 6.  Hypertension in the elderly.

Authors:  M Pestana
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 7.  Optimising diuretic therapy in elderly patients with hypertension.

Authors:  W C Cushman
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

Review 8.  ACE inhibitors. Differential use in elderly patients with hypertension.

Authors:  Z H Israili; W D Hall
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

Review 9.  Hypertension and age-related changes in the heart. Implications for drug therapy.

Authors:  S Isoyama
Journal:  Drugs Aging       Date:  1994-08       Impact factor: 3.923

10.  The effect of a losartan-based treatment regimen on isolated systolic hypertension.

Authors:  William C Cushman; William E Brady; Lisa P Gazdick; Robert K Zeldin
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Mar-Apr       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.